SAGE Therapeutics Sees Unusually High Options Volume (SAGE)

SAGE Therapeutics Inc (NASDAQ:SAGE) saw some unusual options trading activity on Thursday. Traders acquired 2,163 put options on the stock. This represents an increase of approximately 1,323% compared to the typical volume of 152 put options.

Shares of SAGE opened at $105.88 on Friday. SAGE Therapeutics has a one year low of $100.75 and a one year high of $195.97. The stock has a market capitalization of $5.09 billion, a price-to-earnings ratio of -14.93 and a beta of 2.72.

SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) EPS for the quarter, missing the consensus estimate of ($2.41) by ($0.22). During the same period in the prior year, the business posted ($1.97) EPS. Sell-side analysts predict that SAGE Therapeutics will post -7.58 EPS for the current year.



Several institutional investors and hedge funds have recently made changes to their positions in SAGE. Flinton Capital Management LLC boosted its holdings in shares of SAGE Therapeutics by 1,900.0% in the second quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 646 shares during the period. US Bancorp DE boosted its holdings in shares of SAGE Therapeutics by 5,593.3% in the second quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 839 shares during the period. Creative Planning acquired a new position in shares of SAGE Therapeutics in the second quarter worth about $210,000. Tiverton Asset Management LLC acquired a new position in shares of SAGE Therapeutics in the second quarter worth about $229,000. Finally, Opera Trading Capital acquired a new position in shares of SAGE Therapeutics in the third quarter worth about $233,000.

Several research firms have recently weighed in on SAGE. BidaskClub upgraded shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 30th. Oppenheimer set a $170.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research report on Sunday, November 4th. Canaccord Genuity set a $220.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 1st. Cowen restated a “buy” rating and set a $207.00 price objective on shares of SAGE Therapeutics in a research report on Thursday, November 1st. Finally, LADENBURG THALM/SH SH set a $235.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 31st. Two analysts have rated the stock with a sell rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. SAGE Therapeutics has a consensus rating of “Buy” and a consensus target price of $204.14.

TRADEMARK VIOLATION NOTICE: This article was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://dakotafinancialnews.com/2018/12/07/sage-therapeutics-sees-unusually-high-options-volume-sage.html.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Article: Technical Analysis

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply